The April 2005 issue of
Sweet & Maxwell's monthly
European Intellectual Property Review has now been published. This issue leads with an opinion by Colin Davies on access by developing countries to patented medicines in the post-
Glaxo v Dowelhurst and
Doha era. There's also a lengthy review of Community trade mark decisions from Alicante and Luxembourg during 2004 from Arnaud Folliard-Monguiral (OHIM IP Litigation Unit) and David Rogers (European Commission).
Comments
Post a Comment
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html